---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-069624"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2023-03-14T23:59:59+00:00"
generated_at: "2026-06-18T03:00:33.300754+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Larimar reports Q4 2022 net loss $9.4M; Phase 2 CTI-1601 trial on track with data 2H 2023

## Summary
- Net loss of $9.4M ($0.21 per share) in Q4 2022 vs $9.1M ($0.50 per share) in Q4 2021; FY 2022 net loss $35.4M.
- Cash, cash equivalents and marketable securities of $118.4M at Dec 31, 2022, projected runway into 2H 2024.
- Phase 2 trial first cohort (25 mg) of CTI-1601 fully enrolled; update on next steps expected Q2 2023 after FDA/IDMC review.
- Top-line safety, PK and PD (frataxin level) data from both cohorts expected in 2H 2023; Feb 2023 appointed Dr. Gopi Shankar as CDO.

## SEC filing metadata
- accession: 0001193125-23-069624
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2023-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000119312523069624/0001193125-23-069624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000119312523069624/d475352d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-069624
- JSON: https://secwatch.observer/filing/0001193125-23-069624.json
- Plain text: https://secwatch.observer/filing/0001193125-23-069624.txt

## Key facts
- Earnings Releases
  Larimar Therapeutics, Inc. reported the year ended December 31, 2022 results: net income net loss of $35.4 million, EPS $1.37 per share.
  - Period: the year ended December 31, 2022
  - Net income: net loss of $35.4 million
  - EPS: $1.37 per share
  - Result: reported results
  source text: For the full year 2022, the Company reported a net loss of $35.4 million, or $1.37 per share, compared to a net loss of $50.6 million, or $2.95 per share for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374690/000119312523069624/0001193125-23-069624-index.htm
- Earnings Releases
  Larimar Therapeutics, Inc. reported fourth quarter of 2022 results: net income net loss of $9.4 million, EPS $0.21 per share.
  - Period: fourth quarter of 2022
  - Net income: net loss of $9.4 million
  - EPS: $0.21 per share
  - Result: reported results
  source text: The Company reported a net loss for the fourth quarter of 2022 of $9.4 million, or $0.21 per share, compared to a net loss of $9.1 million, or $0.50 per share, for the fourth quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374690/000119312523069624/0001193125-23-069624-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.